Skip to main content
    Z

    Zevra Therapeutics Inc. (ZVRA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.40
    +0.15 (+1.62%)

    Market Cap: $550.42M

    Last updated: Nov 17, 2026 at 4:17 PM ET

    Zevra Therapeutics Inc. (ZVRA) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Zevra Therapeutics (ZVRA) has a market cap of $550.42M and an enterprise value of $428.27M. Revenue grew 75.10% over the last 12 months from the 12 months before. It kept 52.80% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 22.19% below the market cap, as cash exceeds debt.

    Market Cap$550.42M
    Enterprise Value$428.27M
    Latest price (Nov 17, 2026)$9.40

    Key Dates

    The next earnings report is expected on Mar 8, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 8, 2027 (expected)
    Last Earnings DateNov 3, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.43% in the quarter ended Sep 30, 2026 and grew 11.47% a year over 2 years.

    Shares Outstanding59.41M
    Shares Change (YoY)+6.18%
    Shares Change (QoQ)+0.43%
    Share Count Growth (2Y CAGR)+11.47%

    Valuation Ratios

    Sales and book value multiples are 3.8x and 2.3x.

    P/E Ratio11.8x
    Forward P/E8.2x
    P/S Ratio3.8x
    Forward P/S3.6x
    P/B Ratio2.3x
    P/TBV Ratio2.4x
    P/FCF Ratio14.6x
    P/OCF Ratio14.2x
    PEG Ratio0.5

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 5.1x EBITDA and 11.4x free cash flow.

    EV / Earnings5.5x
    EV / Sales2.9x
    EV / EBITDA5.1x
    EV / FCF11.4x

    Price Statistics

    The stock is up 5.86% over 52 weeks and trades 13.44% below its 50-day average.

    Beta (1Y)1.03
    52-Week Change+5.86%
    1-Month Change-7.48%
    3-Month Change-22.51%
    6-Month Change-7.84%
    5-Year Change+8.21%
    10-Year Change-82.64%
    Total Return (1Y)+5.86%
    Total Return (3Y CAGR)+29.38%
    Total Return (5Y CAGR)+2.55%
    Return vs SPY (1Y)-14.65%
    Max Drawdown (1Y)-38.44%
    Max Drawdown (3Y)-43.47%
    Sharpe Ratio (1Y)-0.05
    Correlation with SPY (1Y)0.22
    50-Day Average$10.86
    200-Day Average$10.85
    52-Week Range$8.01 to $15.04
    RSI (14 Days)39.8
    Average Volume (20 Days)1.13M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 5.46x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio5.46x
    Quick Ratio5.38x
    Debt / Equity0.00x
    Interest Coverage-19.06x

    Returns and Efficiency

    Return on equity is 32.65% over the last 12 months, against a 5-year average of -65.80%.

    Return on Equity (ROE)32.65%
    Return on Assets (ROA)24.88%
    ROE (5Y Average)-65.80%
    ROA (5Y Average)-17.27%
    ROIC (5Y Average)-9.99%
    Asset Turnover0.51x
    Inventory Turnover1.89x
    Receivables Turnover6.96x
    Cash Conversion Cycle-722 days

    Taxes

    Income tax took 13.30% of pretax income over the last 12 months.

    Income Tax (TTM)$11.97M
    Effective Tax Rate13.30%

    Scores

    ZVRA has an Altman Z-Score of 4.97, in the safe zone above 2.99, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.

    Altman Z-Score4.97
    Altman Z ZoneSafe
    Piotroski F-Score6 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $147.76M over the last 12 months.

    Revenue$147.76M
    Revenue Growth (YoY)+75.10%
    Gross Profit$142.55M
    Operating Income$89.82M
    Pretax Income$89.98M
    Net Income$78.02M
    Reported EPS (TTM)$0.80

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 76.19% of the $313.57M in total assets.

    Cash and Equivalents$122.15M
    Total Debt$0
    Net Cash$122.15M
    Net Cash Per Share$2.06
    Working Capital$184.47M
    Shareholder Equity$238.92M
    Book Value Per Share$4.02
    Tangible Book Value$228.75M
    Tangible Book Per Share$3.85
    Total Assets$313.57M
    Total Liabilities$74.65M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $521.00K of capital spending, operating cash flow left $38.22M of free cash flow.

    Operating Cash Flow$38.74M
    Capital Expenditures$521.00K
    Free Cash Flow$38.22M
    FCF Per Share$0.64
    Depreciation and Amortization$3.56M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 60.78%.

    Gross Margin96.47%
    Operating Margin60.78%
    Pretax Margin60.90%
    Net Margin52.80%
    FCF Margin25.86%
    Gross Margin (5Y Average)87.16%

    Growth

    Revenue grew 118.82% a year over 3 years.

    Revenue Growth (3Y CAGR)+118.82%
    Revenue Growth (5Y CAGR)+51.62%
    Book Value Per Share Growth (2Y CAGR)+34.66%

    Revenue and profit by year

    Dividends and Yields

    ZVRA does not pay a dividend. Its free cash flow yield is 6.84%.

    Earnings Yield8.47%
    FCF Yield6.84%
    Buyback Yield0.21%
    Shareholder Yield0.21%

    Stock Splits

    The last split was a 1-for-16 reverse split on Dec 28, 2020.

    Last Split DateDec 28, 2020
    Split TypeReverse split
    Split Ratio1:16

    Peer Position

    Against 4 similar companies, ZVRA has the 3rd highest P/S.

    P/S Ratio3.8x vs 5.8x median
    Revenue Growth (Trailing 4 Quarters, YoY)+75.10% vs -99.79% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 28.77% and EPS growth at 284.60% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+28.77%
    EPS Growth Forecast (2Y CAGR)+284.60%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About ZVRA

    What is ZVRA's market cap?

    Zevra Therapeutics has a market cap of $550.42M. Its enterprise value, which adds debt and subtracts cash, is $428.27M.

    What is ZVRA's P/E ratio?

    Zevra Therapeutics has a trailing P/E ratio of 11.8x and a forward P/E of 8.2x.

    How many shares of ZVRA are outstanding?

    Zevra Therapeutics has 59.41M shares outstanding. The count is up 6.18% from a year earlier.

    Does ZVRA pay a dividend?

    No. Zevra Therapeutics does not pay a dividend.

    How much debt does ZVRA have?

    Zevra Therapeutics has $0 of total debt and $122.15M of cash and equivalents, a net cash position of $122.15M.